DUBLIN–(BUSINESS WIRE)–The “Competition Law for the Pharmaceutical Industry Training Course (Feb 27, 2026)” training has been added to ResearchAndMarkets.com’s DUBLIN–(BUSINESS WIRE)–The “Competition Law for the Pharmaceutical Industry Training Course (Feb 27, 2026)” training has been added to ResearchAndMarkets.com’s

EU and UK Competition Law for the Pharmaceutical Industry Online Training Course: Uses Case Studies and Real-world Examples to Address How Compliance Works in Practice (Feb 27, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Competition Law for the Pharmaceutical Industry Training Course (Feb 27, 2026)” training has been added to ResearchAndMarkets.com’s offering.

This comprehensive course is designed to equip professionals in the pharmaceutical sector with the knowledge and tools needed to navigate the complexities of competition law. It will cover the full spectrum of competition law from cooperation with competitors, to abusive life-cycle management, disparagement and the use of IP, to trends in public and private enforcement.

The expert speakers focus on the fundamental principles and key elements of competition law in the EU and UK that apply to the pharmaceutical industry. This is an interactive session that uses case studies and real-world examples from industry to address how compliance works in practice.

By addressing critical legal and operational challenges, participants will gain a clear and pragmatic understanding of how competition law impacts the pharmaceutical supply chain and how this translates to making commercial decisions in their day-to-day activities.

Benefits of attending

  • Understand the role of competition law in the entire pharmaceutical supply chain
  • Update your knowledge on relevant competition law for the pharma industry
  • Learn about horizontal and vertical co-operation
  • Explore portfolio management and dealing with next generation products
  • Get to grips with quota systems and export bans
  • Gain insights into how to be prepared for public enforcement and dawn raids
  • Familiarise yourself with key developments in damages directives, class actions and litigation funding

Who Should Attend:

  • In-house lawyers
  • Compliance managers and regulatory affairs specialists
  • Commercial and contracts managers
  • R&D managers
  • Procurement and supply chain personnel
  • Business development managers
  • Heads of legal departments and legal advisers
  • Patent, IP, trade mark and licensing counsel

Certifications:

  • CPD: 6 hours for your records
  • Certificate of completion

Key Topics Covered:

Introduction and legal landscape

  • Pharmaceutical supply chain & role of competition law
  • Competition law: relevant legislation for the pharmaceutical industry
  • Anticompetitive agreements
  • Abuse of dominance
  • Mergers
  • Where to find help

Horizontal and vertical cooperation in the pharmaceutical industry

  • Commercial agreements
  • Distribution agreements
  • Co-promotion and co-commercialisation
  • R&D
  • IP related agreements and licensing
  • Technology transfer
  • Industry associations and working groups

Unilateral conduct

  • Life-cycle/portfolio management – dealing with next generation products
  • Quota systems and export bans
  • Pricing: rebates, discounts and excessive pricing
  • Parallel trade
  • Disparagement – what can you say about your competitors?
  • IP-related abusive conduct

Case studies

Enforcement of competition law

  • Public enforcement
    • Dawn raid preparedness
    • Leniency
    • Continued regulatory focus on the pharmaceutical industry
  • Private enforcement
    • Key developments: Damages Directive/Class Actions/Litigation Funding
    • Damages claims against pharmaceutical companies
  • Case studies

Speakers:

Niels Ersbøll

Partner

Arnold & Porter LLP

Niels Ersbøll, Partner, Arnold & Porter LLP, advises clients on EU competition law in relation to cartels and restrictive practices, merger control, abuse of dominance, and State aid. He is currently involved in several pending EU cartel investigations. He advises on merger control investigations by the European Commission and competition authorities worldwide for clients such as General Electric, Boston Scientific, Pfizer, and Sanyo.

Where investigations (mergers or cartels) are run by several authorities in parallel, he assists with overall strategy and coordination. Niels also has significant experience helping clients with designing and implementing compliance measures and conducting internal investigations and audits.

For more information about this training visit https://www.researchandmarkets.com/r/drp8gn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0.0751
$0.0751$0.0751
-0.87%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

‘Groundbreaking’: Barry Silbert Reacts to Approval of ETF with XRP Exposure

‘Groundbreaking’: Barry Silbert Reacts to Approval of ETF with XRP Exposure

The post ‘Groundbreaking’: Barry Silbert Reacts to Approval of ETF with XRP Exposure appeared on BitcoinEthereumNews.com. A “combo” ETF  Crypto ETF trailblazer  Digital Currency Group founder Barry Silbert has reacted to the approval of the Grayscale Digital Large Cap Fund  (GDLC), the very first multi-crypto exchange-traded fund (ETF), describing it as “groundbreaking.”  “Grayscale continues to be the first mover, driving new product innovations that bridge tradfi and digital assets,” Silbert said while commenting on the news.  Peter Mintzberg, chief executive officer at Graysacle, claims that the team behind the world’s leading cryptocurrency asset manager is working “expeditiously” in order to bring the product to the market.  A “combo” ETF  The ETF in question offers exposure to Bitcoin (BTC), Ethereum (ETH), as well as several other major altcoins, including the Ripple-linked XRP token, Solana (SOL), and Cardano (ADA). XRP, for instance, has a 5.2% share of the fund, making it the third-largest constituent.  The fund initially debuted as a private placement for accredited investors back in early 2018, and its shares later became available on over-the-counter (OTC) markets.  In early July, the SEC approved the conversion of GDLC into an ETF, but it was then abruptly halted for a “review” shortly after this.  As of Sept. 17, the fund currently has a total of $915.6 million in assets.  Crypto ETF trailblazer  It is worth noting that Grayscale is usually credited with kickstarting the cryptocurrency ETF craze by winning its court case against the SEC.  The SEC ended up approving Bitcoin ETFs in early 2024 and then followed up with Ethereum ETFs.  Grayscale’s flagship GBTC currently boasts more than $20.5 billion in net assets, according to data provided by SoSoValue.  Source: https://u.today/groundbreaking-barry-silbert-reacts-to-approval-of-etf-with-xrp-exposure
Share
BitcoinEthereumNews2025/09/19 03:39
USDC Exchange Inflows Hit $1.33B, Highest in Over Four Years

USDC Exchange Inflows Hit $1.33B, Highest in Over Four Years

The post USDC Exchange Inflows Hit $1.33B, Highest in Over Four Years appeared on BitcoinEthereumNews.com. Key Points: Daily USDC inflow reaches $1.33B, marking a 4-year record Global stablecoin supply surges to an all-time high of $280B USDC market cap grows steadily, reflecting rising institutional interest USDC inflows into centralized exchanges have reached $1.33 billion, the highest level recorded in more than four years. This surge indicates renewed investor interest and suggests a strong return of capital to crypto markets. USDC Exchange Inflow + BTC Price | Source : CryptoQuant The recent inflow occurred in mid-September 2025 and followed consistent large deposits over the past month. Notably, inflows of $1.2 billion and $1 billion were seen in early and late August, respectively. Rising Exchange Inflows Signal Increasing On-Chain Liquidity Large stablecoin inflows to exchanges often signal potential market activity, especially when the volume exceeds historical averages. The $1.33B inflow represents a significant injection of liquidity and indicates increased market readiness. When stablecoins like USDC are sent to exchanges in large amounts, it typically reflects user intent to trade or reposition capital. These actions suggest that investors are preparing for market moves or accumulating digital assets. Global Stablecoin Supply Surges to $280 Billion The global supply of stablecoins has reached an all-time high of $280 billion, showing strong growth from a low of $125 billion in mid-2023. This doubling in supply over two years reflects rising demand for digital dollar-based assets. Global Stablecoin Supply at all-time high of $280 billion | Source : token terminal  This growth indicates broader adoption across use cases such as trading, payments, and decentralized finance. The consistent increase in outstanding supply also reflects capital inflows from both institutional and retail users. USDC Sees Steady Growth in Market Share and Trust USDC’s market capitalization has climbed to approximately $63 billion, continuing its recovery from previous lows. This steady rise signals improving market sentiment…
Share
BitcoinEthereumNews2025/09/19 17:12
HyperGPT and ByteNova Ally to Build a User-Owned AI and Web3 Ecosystem

HyperGPT and ByteNova Ally to Build a User-Owned AI and Web3 Ecosystem

HyperGPT teams up with ByteNova to enable user-owned AI, decentralized applications (dApps), digital assets, and next-gen Web3 innovation for global developers.
Share
Blockchainreporter2025/11/15 14:30